Association between Adherence to Guideline-Recommended Preventive Medications and In-Hospital Mortality among Non-Reperfused ST-Elevation Myocardial Infarction Patients Admitted to a Tertiary Care Academic Center in a Developing Country.
Indonesia
ST-elevation myocardial infarction
STEMI
developing countries
guideline adherence
hospital mortality
no reperfusion therapy
Journal
Global heart
ISSN: 2211-8179
Titre abrégé: Glob Heart
Pays: England
ID NLM: 101584391
Informations de publication
Date de publication:
06 02 2020
06 02 2020
Historique:
entrez:
4
6
2020
pubmed:
4
6
2020
medline:
14
4
2021
Statut:
epublish
Résumé
Acute ST-elevation myocardial infarction (STEMI) is a potentially fatal presentation of coronary artery disease (CAD). Evidence of the impact of acute pharmacological interventions in non-reperfused STEMI patients on subsequent events is limited. We aimed to assess the association between adherence to guideline-recommended preventive medications and in-hospital mortality among this high-risk patient population. We conducted a cohort study using data obtained from the Jakarta Acute Coronary Syndrome (JAC) Registry database from a tertiary care academic hospital in Indonesia. We included 1132 of 2694 patients with STEMI recorded between 1 January 2014 and 31 December 2016 who did not undergo acute reperfusion therapy. Adherence to guideline-recommended preventive medications was defined as the combined administration of aspirin, clopidogrel, anticoagulants and statins after hospital admission. The main outcome measure was in-hospital mortality. Overall, 778 of 1132 patients (69%) received the combination of preventive medications. The guideline non-adherent group had significantly more patients with earlier onset of STEMI, higher Killip class and thrombolysis in myocardial infarction (TIMI) score. After adjustments for measured characteristics using logistic regression modeling, exposure to the combination of preventive therapies was associated with a statistically significant lower risk for in-hospital mortality (adjusted odds ratio: 0.46, 95% confidence interval: 0.30-0.70). Adherence to guideline-recommended preventive medications was associated with lower risk of in-hospital mortality in non-reperfused STEMI patients. The predictors of not receiving these medications need to be confirmed in future research.
Sections du résumé
Background and aims
Acute ST-elevation myocardial infarction (STEMI) is a potentially fatal presentation of coronary artery disease (CAD). Evidence of the impact of acute pharmacological interventions in non-reperfused STEMI patients on subsequent events is limited. We aimed to assess the association between adherence to guideline-recommended preventive medications and in-hospital mortality among this high-risk patient population.
Methods
We conducted a cohort study using data obtained from the Jakarta Acute Coronary Syndrome (JAC) Registry database from a tertiary care academic hospital in Indonesia. We included 1132 of 2694 patients with STEMI recorded between 1 January 2014 and 31 December 2016 who did not undergo acute reperfusion therapy. Adherence to guideline-recommended preventive medications was defined as the combined administration of aspirin, clopidogrel, anticoagulants and statins after hospital admission. The main outcome measure was in-hospital mortality.
Results
Overall, 778 of 1132 patients (69%) received the combination of preventive medications. The guideline non-adherent group had significantly more patients with earlier onset of STEMI, higher Killip class and thrombolysis in myocardial infarction (TIMI) score. After adjustments for measured characteristics using logistic regression modeling, exposure to the combination of preventive therapies was associated with a statistically significant lower risk for in-hospital mortality (adjusted odds ratio: 0.46, 95% confidence interval: 0.30-0.70).
Conclusions
Adherence to guideline-recommended preventive medications was associated with lower risk of in-hospital mortality in non-reperfused STEMI patients. The predictors of not receiving these medications need to be confirmed in future research.
Identifiants
pubmed: 32489781
doi: 10.5334/gh.394
pmc: PMC7218801
doi:
Substances chimiques
Cardiovascular Agents
0
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
8Informations de copyright
Copyright: © 2020 The Author(s).
Déclaration de conflit d'intérêts
The authors have no competing interests to declare.
Références
J Am Coll Cardiol. 2010 May 4;55(18):1895-906
pubmed: 20430260
Int J Cardiol. 2018 Dec 1;272:26-32
pubmed: 30121176
Am Heart J. 2008 Dec;156(6):1080-1088.e1
pubmed: 19033002
BMJ Open. 2016 Sep 26;6(9):e012193corr1
pubmed: 27678538
J Am Coll Cardiol. 2013 Jan 29;61(4):e78-e140
pubmed: 23256914
Clin Cardiol. 2015 Jun;38(6):327-32
pubmed: 26074496
Am J Cardiol. 2011 Feb 15;107(4):501-8
pubmed: 21195380
BMJ. 2006 Nov 25;333(7578):1091
pubmed: 17032691
JAMA. 1998 Nov 18;280(19):1690-1
pubmed: 9832001
Lancet. 2005 Nov 5;366(9497):1607-21
pubmed: 16271642
PLoS Med. 2007 Oct 16;4(10):e297
pubmed: 17941715
Am J Cardiol. 2018 Feb 15;121(4):403-409
pubmed: 29290368
Circulation. 2014 Apr 8;129(14):1493-501
pubmed: 24573351
JAMA. 2005 Jun 15;293(23):2865-72
pubmed: 15956631
Heart. 2010 Jul;96(14):1095-101
pubmed: 20511625
Eur Heart J. 2012 Oct;33(20):2569-619
pubmed: 22922416
Int J Epidemiol. 2019 Aug 1;48(4):1367-1376
pubmed: 30629192
Eur Heart J. 2016 Jan 14;37(3):267-315
pubmed: 26320110
PLoS One. 2017 Apr 7;12(4):e0175485
pubmed: 28388683
Circ Cardiovasc Qual Outcomes. 2013 Jul;6(4):436-43
pubmed: 23800985
Eur Heart J. 2008 Feb;29(3):315-23
pubmed: 18084015
Int J Cardiol. 2015 Mar 15;183:63-75
pubmed: 25662044
Atherosclerosis. 2015 Jul;241(1):151-6
pubmed: 25988359
Eur Heart J. 2018 Nov 7;39(42):3807-3809
pubmed: 30247536
Eur Heart J. 2014 Aug 1;35(29):1957-70
pubmed: 24419804
Eur Heart J. 2018 Nov 7;39(42):3798-3806
pubmed: 30202849
Eur Heart J. 2006 Jul;27(13):1539-49
pubmed: 16760203
Lancet. 2015 Jan 10;385(9963):117-71
pubmed: 25530442
PLoS One. 2014 Feb 10;9(2):e86665
pubmed: 24520322
J Am Coll Cardiol. 2014 Dec 23;64(24):e139-e228
pubmed: 25260718
PM R. 2011 Mar;3(3):263-7
pubmed: 21402371
Rev Esp Cardiol (Engl Ed). 2017 Dec;70(12):1082
pubmed: 29198432
Am Heart J. 2016 Feb;172:1-8
pubmed: 26856209
Trop Med Int Health. 2015 May;20(5):627-637
pubmed: 25640658
Eur J Cardiovasc Prev Rehabil. 2010 Oct;17(5):576-81
pubmed: 20351550
Open Heart. 2015 May 21;2(1):e000240
pubmed: 26019883
Neth Heart J. 2012 Jun;20(6):254-9
pubmed: 22328356
Eur Heart J. 2005 May;26(9):873-80
pubmed: 15681575
J Am Coll Cardiol. 2003 Oct 15;42(8):1348-56
pubmed: 14563573
Lancet. 2016 Oct 8;388(10053):1459-1544
pubmed: 27733281
BMJ Open. 2017 Oct 5;7(10):e017008
pubmed: 28982823
Ann Transl Med. 2016 Jul;4(13):256
pubmed: 27500157